Condition: Diffuse Large B-cell-lymphoma · DLBCL, Nos Genetic Subtypes · Follicular Lymphoma Grade 3B · Sponsor: Shanghai Exuma Biotechnology Ltd.
This study is to investigate the safety and tolerability of C402-CD19-CAR treatment in subjects with relapsed or refractory large B-cell lymphoma and further determine the recommended Phase 2 dose of C402-CD19-CAR.
This description comes directly from the study's public registry record.
Shihan Jie · 0086-15251756783 · shihan.jie@kuntuo.com
Liujin Sai, master · 0086-15702443608 · liujin.sai@kuntuo.com
Always discuss trial participation with your own doctor first.
| Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences | Tianjin, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06830031